Last $77.05 USD
Change Today +1.47 / 1.94%
Volume 1.2M
INCY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

incyte corp (INCY) Snapshot

Open
$76.36
Previous Close
$75.58
Day High
$77.85
Day Low
$75.88
52 Week High
12/8/14 - $80.78
52 Week Low
04/15/14 - $40.30
Market Cap
13.0B
Average Volume 10 Days
1.3M
EPS TTM
$-0.29
Shares Outstanding
168.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INCYTE CORP (INCY)

incyte corp (INCY) Related Businessweek News

No Related Businessweek News Found

incyte corp (INCY) Details

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs primarily for oncology and inflammation. The company markets JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, a JAK inhibitor, which is in Phase III clinical trial for polycythemia vera; in Phase II trial for pancreatic cancer; and in Phase I trial for the treatment of malignancies, as well as baricitinib, a JAK inhibitor, which is in Phase III trial for rheumatoid arthritis, in Phase IIb trial for psoriasis, and in Phase II trial for diabetic nephropathy. The company’s products in pipeline also comprise INC280, which is in Phase II clinical trial for the treatment of solid tumors, hepatocellular carcinoma, and non-small cell lung cancer; and INCB24360 that is in Phase II clinical trial for the treatment of metastatic melanoma and ovarian cancer; INCB40093 and INCB39110+INCB40093, which are Phase I clinical trial products for the treatment of B-lymphoid malignancies; INCB39110 that is in Phase II for myelofibrosis treatment and in Phase I for the treatment of malignancies; and INCB47986, which is in Phase I clinical trial products for the treatment of rheumatoid arthritis. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc., as well as strategic collaboration arrangement with Merck. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

481 Employees
Last Reported Date: 02/21/14
Founded in 1991

incyte corp (INCY) Top Compensated Officers

Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $506.6K
Chief Drug Development & Medical Officer and ...
Total Annual Compensation: $373.4K
Executive Vice President of Human Resources
Total Annual Compensation: $354.0K
Compensation as of Fiscal Year 2013.

incyte corp (INCY) Key Developments

FDA Approves Incyte Corporation's Jakafi(R) (Ruxolitinib) for Treatment of Patients with Uncontrolled Polycythemia Vera

Incyte Corporation announced that the U.S. Food and Drug Administration has approved Jakafi(R) (ruxolitinib) for the treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi, an oral medication, is the first and only product approved by the FDA for PV, a rare and progressive blood cancer. PV is a myeloproliferative neoplasm (MPN) and is typically characterized by elevated hematocrit, the volume percentage of red blood cells in whole blood, which can lead to a thickening of the blood and an increased risk of blood clots, as well as an elevated white blood cell and platelet count. PV may occur at any age but often presents later in life, with a median age at diagnosis of 60 years(1,2). Approximately 100,000 patients in the U.S. are living with PV. Current standard treatment for PV is phlebotomy (the removal of blood from the body) plus aspirin. When phlebotomy can no longer control PV, chemotherapy such as hydroxyurea, or interferon, is utilized(4,5) . Approximately one in four (25,000) patients with PV are considered uncontrolled(6,7) because they have an inadequate response to or are intolerant of hydroxyurea, the most commonly used chemotherapeutic agent for the treatment of PV. Patients with PV who fail to consistently maintain appropriate blood count levels, including appropriate hematocrit levels, have an approximately four times higher risk of major thrombosis (blood clots) or cardiovascular death. Patients with PV can also suffer from an enlarged spleen, and a significant symptom burden which may be attributed to thickening of the blood and a lack of oxygen to parts of the body. These symptoms commonly include fatigue, itching, night sweats, bone pain, fever, and weight loss. Jakafi is FDA-approved product for the treatment of intermediate or high-risk myelofibrosis, a closely related blood cancer. Jakafi is a JAK1 and JAK2 inhibitor that targets overactive JAK pathway signaling, which plays a critical role in the development of both myelofibrosis and polycythemia vera. The approval of Jakafi for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea was based on data from the pivotal Phase III RESPONSE trial, which was conducted under a Special Protocol Assessment from the FDA. In this trial, patients treated with Jakafi demonstrated superior hematocrit control and reductions in spleen volume compared to best available therapy. In addition, a greater proportion of patients on the ruxolitinib treatment arm achieved complete hematologic remission - which was defined as achieving hematocrit control, and lowering platelet and white blood cell counts. In the RESPONSE trial, the most common hematologic adverse reactions (incidence > 20%) were thrombocytopenia and anemia. The most common non-hematologic adverse events (incidence >10%) were headache, abdominal pain, diarrhea, dizziness, fatigue, pruritus, dyspnea and muscle spasms.

Incyte Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 12:00 PM

Incyte Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 12:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States.

Incyte Corporation Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 10:20 AM

Incyte Corporation Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 10:20 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: James M. Daly, Chief Commercial Officer and Executive Vice President, Richard S. Levy, Chief Drug Development & Medical Officer and Executive Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INCY:US $77.05 USD +1.47

INCY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $6.61 USD +0.25
Array BioPharma Inc $4.80 USD +0.09
Evotec AG €3.70 EUR +0.139
GlaxoSmithKline SAE £12.37 EGP 0.00
Infinity Pharmaceuticals Inc $17.19 USD +0.25
View Industry Companies
 

Industry Analysis

INCY

Industry Average

Valuation INCY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 25.1x
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INCYTE CORP, please visit www.incyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.